• Sign In
  • Create Account
  • My Account

  • Signed in as:

  • filler@godaddy.com

  • My Account

  • Sign out

  • Home
  • About
    • About Us
    • Collaborations
    • Become a Member
  • Education
  • News & Publications
    • For Patients & Public
    • Newsletters
    • Publications
  • Committees
  • Resources
    • Governance and Policies
    • Questionnaires
    • Submit a proposal
    • Request a travel grant
    • Network Contacts
    • Current Research Projects
    • Site Log-in
    • Graphs and Charts
    • Available Samples
    • CIDsCaNN-MAGIC
  • Contact Us
  • More
    • Home
    • About
      • About Us
      • Collaborations
      • Become a Member
    • Education
    • News & Publications
      • For Patients & Public
      • Newsletters
      • Publications
    • Committees
    • Resources
      • Governance and Policies
      • Questionnaires
      • Submit a proposal
      • Request a travel grant
      • Network Contacts
      • Current Research Projects
      • Site Log-in
      • Graphs and Charts
      • Available Samples
      • CIDsCaNN-MAGIC
    • Contact Us

Signed in as:

filler@godaddy.com

  • Home
  • About
    • About Us
    • Collaborations
    • Become a Member
  • Education
  • News & Publications
    • For Patients & Public
    • Newsletters
    • Publications
  • Committees
  • Resources
    • Governance and Policies
    • Questionnaires
    • Submit a proposal
    • Request a travel grant
    • Network Contacts
    • Current Research Projects
    • Site Log-in
    • Graphs and Charts
    • Available Samples
    • CIDsCaNN-MAGIC
  • Contact Us

Account

  • My Account

  • Sign out

  • Sign In
  • My Account

Therapy Graphs

Initial Induction Protocol

Time to First Therapy

Download date: October 4th, 2021 

n=1466

Time to First Therapy - Crohn's Disease

Download date: October 4th, 2021

n=939

Time to First Therapy - Ulcerative Colitis

Download date: October 4th, 2021 

n=482

Durability of Anti-TNF Therapy

Download Date: October 4th, 2021 

Infliximab (n=785)  Adalimumab (n=261)

ADA after IFX (n=44)  IFX after ADA (n=32)

The Canadian Children Inflammatory Bowel Disease Network

555 University Avenue,

Toronto ON

Canada M5G 1X8

email: info@cidscann.ca


Copyright © 2019 The Canadian Children Inflammatory Bowel Disease Network - All Rights Reserved.

Powered by GoDaddy Website Builder